Proteonomix Inc (PROT) 0.0250 $PROT
Planet Fitness Launches New Advertising Creative In 2014, Continues To Tackle "Gymtimidation"
PR Newswire - Tue Jan 14, 11:00AM CST
Planet Fitness, the innovative health club franchise known for its Judgement Free Zone® and affordable prices, today announced four new national TV spots to air throughout 2014. The spots, which are an extension of the successful "No Gymtimidation" campaign launched in 2013, continue to differentiate the brand as a health club void of "lunky" behaviors that often intimidate people or ruin their gym experience.
Proteonomix Settles Litigation
PR Newswire - Mon Apr 01, 12:01PM CDT
Proteonomix, Inc. (OTC: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that it has settled investor litigation upon the following terms and conditions:
Proteonomix To Require Physical Exchange Of Certificates
PR Newswire - Thu Jan 10, 10:49AM CST
Proteonomix, Inc. (the "Company"
(OTC Pink: PROT), a biotechnology company (the "Company" focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that upon its name change to StromaCel, Inc., presently scheduled for January 18, 2013, all shareholders will be required to submit their stock certificates to our transfer agent, VStock Transfer, in order to obtain their new share certificates in the Company.
Proteonomix Announces Restructuring
PR Newswire - Tue Jan 08, 8:42AM CST
Proteonomix, Inc. (the "Company" (SYMBOL: PROT), a biotechnology company (the "Company" focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has caused the formation of a BVI corporation that will receive sublicenses and assignments of technology previously licensed to the Company so as to facilitate future financing and operations.
Proteonomix Updates Status Of UMK-121 Testing
PR Newswire - Tue Jan 08, 8:40AM CST
Proteonomix, Inc. (the "Company" (Symbol PROT), a biotechnology company (the "Company" focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the University of Medicine & Dentistry of New Jersey (UMDNJ) in conjunction with the Company has commenced enrollment of patients with End Stage Liver Disease (ESLD) in its clinical trial of UMK-121.
Planet Fitness Launches New Advertising Creative In 2014, Continues To Tackle "Gymtimidation"
PR Newswire - Tue Jan 14, 11:00AM CST
Planet Fitness, the innovative health club franchise known for its Judgement Free Zone® and affordable prices, today announced four new national TV spots to air throughout 2014. The spots, which are an extension of the successful "No Gymtimidation" campaign launched in 2013, continue to differentiate the brand as a health club void of "lunky" behaviors that often intimidate people or ruin their gym experience.
Proteonomix Settles Litigation
PR Newswire - Mon Apr 01, 12:01PM CDT
Proteonomix, Inc. (OTC: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that it has settled investor litigation upon the following terms and conditions:
Proteonomix To Require Physical Exchange Of Certificates
PR Newswire - Thu Jan 10, 10:49AM CST
Proteonomix, Inc. (the "Company"
(OTC Pink: PROT), a biotechnology company (the "Company" focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that upon its name change to StromaCel, Inc., presently scheduled for January 18, 2013, all shareholders will be required to submit their stock certificates to our transfer agent, VStock Transfer, in order to obtain their new share certificates in the Company. Proteonomix Announces Restructuring
PR Newswire - Tue Jan 08, 8:42AM CST
Proteonomix, Inc. (the "Company"
(SYMBOL: PROT), a biotechnology company (the "Company" focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it has caused the formation of a BVI corporation that will receive sublicenses and assignments of technology previously licensed to the Company so as to facilitate future financing and operations. Proteonomix Updates Status Of UMK-121 Testing
PR Newswire - Tue Jan 08, 8:40AM CST
Proteonomix, Inc. (the "Company"
(Symbol PROT), a biotechnology company (the "Company" focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the University of Medicine & Dentistry of New Jersey (UMDNJ) in conjunction with the Company has commenced enrollment of patients with End Stage Liver Disease (ESLD) in its clinical trial of UMK-121. 
